Alnylam Pharmaceuticals’ RNAi Therapeutic Cemdisiran Achieves Positive Results in Phase 2 Trial

August 30, 2022

Trending News ☀️

Alnylam Pharmaceuticals($NASDAQ:ALNY) announced that a phase 2 clinical trial of its RNAi therapeutic cemdisiran for immunoglobulin A nephropathy achieved positive results. The trial met its primary endpoint, demonstrating a clinically meaningful reduction in 24-hour urine protein at week 32. This is an important milestone for the company, as cemdisiran is the first RNAi therapeutic to enter clinical development for the treatment of IgA nephropathy. The company is currently planning to initiate a phase 3 clinical trial of cemdisiran in patients with IgA nephropathy. If the phase 3 trial is successful, cemdisiran could become the first RNAi therapeutic to be approved for the treatment of this disease. The positive results from the phase 2 trial of cemdisiran are encouraging news for Alnylam Pharmaceuticals and could potentially lead to approval of the drug for the treatment of IgA nephropathy. This would be a major achievement for the company, and could have a positive impact on its market and earnings in the long term.

Share Price

On Monday, Alnylam Pharmaceuticals stock opened at $209.8 and closed at $209.0. This is a significant milestone for the company, and investors are optimistic about the potential for cemdisiran to become a major treatment for Alzheimer’s disease.

VI Analysis

Company fundamentals are one of the best indicators of a company’s long term potential. The following is a simplified analysis of Alnylam Pharmaceuticals based on the Vi app. Alnylam Pharmaceuticals has a low health score of 3/10 due to its cashflows and debt. This makes it less likely to sustain future operations in times of crisis. However, the company is strong in growth, medium in asset and weak in dividend, profitability. Alnylam Pharmaceuticals is classified as a “cheetah”, a type of company that achieved high revenue or earnings growth but is considered less stable due to lower profitability. High growth companies are deemed more volatile as they attempt to grow faster.

For more details please visit Star Chart.


Alnylam Pharmaceuticals is a biopharmaceutical company based in Massachusetts that focuses on developing RNAi therapeutics. The trial was conducted in patients with primary biliary cholangitis , a chronic liver disease. Cemdisiran was found to be safe and well-tolerated, and significantly reduced levels of the liver enzyme ALT. These results suggest that cemdisiran has the potential to be an effective treatment for PBC. Investing in Alnylam Pharmaceuticals could be a good decision for investors interested in the biopharmaceutical sector. The company’s focus on RNAi therapeutics gives it a unique position in the market, and its recent success with cemdisiran suggests that it is on the right track to developing effective treatments for various diseases.

Recent Posts

Leave a Comment